Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
about
Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
P2860
Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase I clinical trial of alte ...... eavily treated ovarian cancer.
@ast
Phase I clinical trial of alte ...... eavily treated ovarian cancer.
@en
type
label
Phase I clinical trial of alte ...... eavily treated ovarian cancer.
@ast
Phase I clinical trial of alte ...... eavily treated ovarian cancer.
@en
prefLabel
Phase I clinical trial of alte ...... eavily treated ovarian cancer.
@ast
Phase I clinical trial of alte ...... eavily treated ovarian cancer.
@en
P2093
P50
P1433
P1476
Phase I clinical trial of alte ...... heavily treated ovarian cancer
@en
P2093
Jong Ha Hwang
Sang-Soo Seo
Sang-Yoon Park
P304
P356
10.1097/CAD.0B013E32834EA5D0
P577
2012-03-01T00:00:00Z